AstraZeneca Other Non-Current Liabilities 2010-2024 | AZN
AstraZeneca other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- AstraZeneca other non-current liabilities for the quarter ending September 30, 2024 were $3.270B, a 6.78% decline year-over-year.
- AstraZeneca other non-current liabilities for 2023 were $3.825B, a 28.24% decline from 2022.
- AstraZeneca other non-current liabilities for 2022 were $5.33B, a 10.18% decline from 2021.
- AstraZeneca other non-current liabilities for 2021 were $5.934B, a 11.03% decline from 2020.
AstraZeneca Annual Other Non-Current Liabilities
(Millions of US $) |
| 2023 |
$3,825 |
| 2022 |
$5,330 |
| 2021 |
$5,934 |
| 2020 |
$6,670 |
| 2019 |
$7,150 |
| 2018 |
$7,159 |
| 2017 |
$8,191 |
| 2016 |
$9,958 |
| 2015 |
$7,902 |
| 2014 |
$8,475 |
| 2013 |
$2,919 |
| 2012 |
$1,429 |
| 2011 |
$859 |
| 2010 |
$1,216 |
| 2009 |
$4,075 |
AstraZeneca Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-09-30 |
$3,270 |
| 2024-06-30 |
$3,343 |
| 2024-03-31 |
$3,770 |
| 2023-12-31 |
$3,825 |
| 2023-09-30 |
$3,508 |
| 2023-06-30 |
$3,823 |
| 2023-03-31 |
$4,447 |
| 2022-12-31 |
$5,330 |
| 2022-09-30 |
$6,102 |
| 2022-06-30 |
$5,082 |
| 2022-03-31 |
$4,752 |
| 2021-12-31 |
$5,934 |
| 2021-09-30 |
$5,872 |
| 2021-06-30 |
$5,815 |
| 2021-03-31 |
$5,725 |
| 2020-12-31 |
$6,670 |
| 2020-09-30 |
$7,327 |
| 2020-06-30 |
$7,100 |
| 2020-03-31 |
$7,216 |
| 2019-12-31 |
$7,150 |
| 2019-09-30 |
$7,893 |
| 2019-06-30 |
$7,351 |
| 2019-03-31 |
$7,259 |
| 2018-12-31 |
$7,159 |
| 2018-09-30 |
$8,284 |
| 2018-06-30 |
$8,470 |
| 2018-03-31 |
$8,357 |
| 2017-12-31 |
$8,191 |
| 2017-09-30 |
$10,197 |
| 2017-06-30 |
$9,780 |
| 2017-03-31 |
$9,981 |
| 2016-12-31 |
$9,958 |
| 2016-09-30 |
$11,263 |
| 2016-06-30 |
$11,471 |
| 2016-03-31 |
$11,086 |
| 2015-12-31 |
$7,902 |
| 2015-09-30 |
$8,337 |
| 2015-06-30 |
$8,458 |
| 2015-03-31 |
$8,600 |
| 2014-12-31 |
$8,475 |
| 2014-09-30 |
$7,463 |
| 2014-06-30 |
$7,530 |
| 2014-03-31 |
$7,730 |
| 2013-12-31 |
$2,919 |
| 2013-09-30 |
$1,702 |
| 2013-06-30 |
$1,655 |
| 2013-03-31 |
$1,715 |
| 2012-12-31 |
$1,429 |
| 2012-09-30 |
$1,606 |
| 2012-06-30 |
$1,680 |
| 2012-03-31 |
$1,003 |
| 2011-12-31 |
$859 |
| 2011-09-30 |
$1,060 |
| 2011-06-30 |
$1,155 |
| 2011-03-31 |
$1,071 |
| 2010-12-31 |
$3,688 |
| 2010-09-30 |
$4,837 |
| 2010-06-30 |
$4,184 |
| 2010-03-31 |
$3,969 |
| 2009-12-31 |
$4,075 |
| 2009-09-30 |
$3,667 |
| 2009-06-30 |
$3,782 |
| 2009-03-31 |
$3,821 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$197.819B |
$45.811B |
|
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
|
